Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
PNT-2001 by Eli Lilly and Co for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval
PNT-2001 is under clinical development by Eli Lilly and Co and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer...